The second committee discussion of liraglutide for managing overweight and obesity is to be rescheduled. The reschedule will ensure there is sufficient time and technical support to fully consider any new evidence submitted in response to the ACD. This webpage will be updated with the date for discussion of this topic once the next available slot has been identified.